JP2024540183A5 - - Google Patents

Info

Publication number
JP2024540183A5
JP2024540183A5 JP2024525662A JP2024525662A JP2024540183A5 JP 2024540183 A5 JP2024540183 A5 JP 2024540183A5 JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024540183 A5 JP2024540183 A5 JP 2024540183A5
Authority
JP
Japan
Prior art keywords
preparation
prevention
treatment
compound
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/129479 external-priority patent/WO2023078333A1/zh
Publication of JP2024540183A publication Critical patent/JP2024540183A/ja
Publication of JP2024540183A5 publication Critical patent/JP2024540183A5/ja
Pending legal-status Critical Current

Links

JP2024525662A 2021-11-03 2022-11-03 置換されたフェニルプロピオン酸誘導体及びその使用 Pending JP2024540183A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111293711.9 2021-11-03
CN202111293711 2021-11-03
CN202211033065 2022-08-26
CN202211033065.7 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (2)

Publication Number Publication Date
JP2024540183A JP2024540183A (ja) 2024-10-31
JP2024540183A5 true JP2024540183A5 (https=) 2026-03-19

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525662A Pending JP2024540183A (ja) 2021-11-03 2022-11-03 置換されたフェニルプロピオン酸誘導体及びその使用

Country Status (10)

Country Link
US (1) US20250042847A1 (https=)
EP (1) EP4428129A4 (https=)
JP (1) JP2024540183A (https=)
KR (1) KR20240091010A (https=)
CN (1) CN118055927A (https=)
AU (1) AU2022381258A1 (https=)
CA (1) CA3235992A1 (https=)
MX (1) MX2024005304A (https=)
TW (1) TW202334116A (https=)
WO (1) WO2023078333A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119894882A (zh) * 2023-04-21 2025-04-25 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
WO2024230805A1 (zh) * 2023-05-11 2024-11-14 江苏恒瑞医药股份有限公司 一种脂蛋白化合物晶型及其制备方法
WO2025024218A1 (en) * 2023-07-21 2025-01-30 Eli Lilly And Company PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
WO2025024210A1 (en) * 2023-07-21 2025-01-30 Eli Lilly And Company Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
US20250179055A1 (en) * 2023-11-17 2025-06-05 Innovstone Therapeutics Limited Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof
WO2025108255A1 (zh) * 2023-11-20 2025-05-30 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
CN121609698A (zh) * 2026-01-30 2026-03-06 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894195A (zh) * 2000-10-11 2007-01-10 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的醚化合物以及组合物
CA2425311C (en) * 2000-10-11 2011-06-14 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
JP2007525408A (ja) * 2003-12-24 2007-09-06 エスペリオン セラピューティクス,インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2231615A1 (en) * 2007-12-10 2010-09-29 7TM Pharma A/S Cannabinoid receptor modulators
US11286249B2 (en) 2019-06-07 2022-03-29 Eli Lilly And Company Pyrrolidine compounds
WO2023146785A1 (en) * 2022-01-26 2023-08-03 Eli Lilly And Company Pyrrolidine compounds

Similar Documents

Publication Publication Date Title
JP2024540183A5 (https=)
JP2021063088A5 (https=)
JP2023002662A5 (https=)
JP2015526458A5 (https=)
JP2022191257A5 (https=)
JP2017528507A5 (https=)
JP2004522714A5 (https=)
JP2009535352A5 (https=)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2019533660A5 (https=)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2024511973A5 (https=)
JP2021502392A5 (https=)
JP2022533968A5 (https=)
JP2022551691A5 (https=)
JP2005508963A5 (https=)
JP2022531251A5 (https=)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
JP2005502579A5 (https=)
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JP2024523559A5 (https=)
JP2023553253A5 (https=)
JP2009500045A5 (https=)
JP2019507786A5 (https=)
JP2013536206A5 (https=)